Aelis Farma SA (AELIS.PA)
- Business Wire
Aelis Farma: Availability of the 2024 Half-year Financial Report
BORDEAUX, France, September 26, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 - ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announces that its half-year financial report has been made available to the public and filled with the French Financial Markets Authority (Autorité des marchés financiers).
- Business Wire
Aelis Farma Announces Half-year Financial Results for 2024 and Provides Corporate and Development Update
BORDEAUX, France, September 25, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces its results for the first half of 2024 and provides an update on its development.
- Business Wire
Aelis Farma Announces the Results of Its Clinical Phase 2B Study with AEF0117, Among Participants with Cannabis Use Disorder (CUD)
BORDEAUX, France, September 04, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces results from the clinical Phase 2B trial conducted by Aelis Farma with AEF01171, evaluating its efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD) that used cannabis ≥5 days/week at baseline. In this study populatio
